CTOs on the Move


 
Founded in 1998, Novation is the leading health care supply chain expertise, analytics and contracting company for the more than 100,000 members of VHA Inc. and UHC, two national health care alliances, Children's Hospital Association, an alliance of the nation's leading pediatric facilities, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC, Children’s Hospital Association, and Provista members used Novation contracts to purchase more than $43 billion in 2012.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Family Home Health Services

Family Home Health Services is a Monroeville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Injury Care Associates

Injury Care Associates is a physician-led occupational health clinic that specializes in helping employees get back to work and back to life after an injury. They offer workers compensation and employee health services in the Denver metro area.

Urgent Cares of America

Urgent Cares of America is a Clayton, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Planned Parenthood of Orange and San Bernardino Counties

Planned Parenthood is the leading provider of reproductive health care in the country. At Planned Parenthood of Orange and San Bernardino Counties, we fight for the fundamental right of all individuals to determine their own destiny.

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.